NY-AMERICAN-EXPRESS
16.9.2020 15:02:23 CEST | Business Wire | Press release
Today, American Express (NYSE: AXP) announced plans to expand two of its signature Centurion Lounges and introduced The Centurion Lounge Commitment, a set of new health and safety protocols and practices, which will be implemented in all Centurion Lounges as they reopen (some starting in early October). The Centurion Lounge at New York's LaGuardia Airport (LGA) will relocate to a larger location in the brand new Terminal B, and as previously announced, the current Centurion Lounge at Las Vegas’ McCarran International Airport (LAS), will be expanded and redesigned.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005291/en/
“The health, safety and comfort of our Card Members and colleagues remains our top priority as we look to expand and reopen our iconic Centurion Lounges around the world,” said Alexander Lee, Vice President Travel Experiences & Benefits. “We believe travel is core to our Card Members’ lifestyles, and like them, we look forward to the day when we can travel the world again - we’re excited to welcome them back into our Centurion Lounges soon.”
Upgrading the Centurion Lounge Experience at LAS and LGA:
Renovations to The Centurion Lounges at New York's LaGuardia Airport and Las Vegas’ McCarran International Airport will be completed in 2021. The expanded lounges will feature a suite of amenities for Card Members to enjoy when they resume traveling.
- The Centurion Lounge at LGA will double in size and relocate to a space post-security within the airport’s brand-new, state-of-the-art Terminal B. The new lounge will feature a family room, additional workspaces, private telephone rooms, and views of the New York City skyline.
- The footprint of the first-ever Centurion Lounge, opened at LAS in 2013, will be expanded from nearly 9,000 square feet to over 13,400 square feet. The newly designed lounge will feature additional multi-purpose areas, new private telephone rooms, newly designed reception and workspace areas and more.
American Express is also working towards opening its newest lounge locations later this year in New York’s John F. Kennedy Airport, London’s Heathrow Airport and Denver International Airport.
Creating a Healthy and Safe Environment with The Centurion Lounge Commitment:
While our Centurion Lounges continue to be closed due to COVID-19, American Express is introducing The Centurion Lounge Commitment to further support the health and safety of Card Members and colleagues when the lounges reopen. According to the Amex Trendex*, a trend report from American Express, nearly 2 in 3 consumers say either health and safety policies and procedures (39%) or flexibility (25%) is most important as they look to book future travel.
Card Members will experience new health and safety practices such as socially distanced seating, reduced capacity, increased cleaning frequency, requirements to wear a face covering when entering the lounge, served food instead of buffets, and more. For a contactless check-in experience, Card Members can download the American Express® App and use the Mobile Check-in Feature. These practices will be re-evaluated on an ongoing basis to take into account Card Members’ needs and the requirements of state and local governments and health authorities. Learn more here: thecenturionlounge.com/reopening .
While some may not be ready to travel today, the Amex Trendex* found over half (56%) of consumers who typically travel domestically anticipate feeling comfortable traveling to a domestic destination within six months. American Express is evaluating when to reopen its Centurion Lounge locations based on several factors, including local COVID-19 case prevalence, and will be taking a phased approach, location by location. The company expects to reopen the Centurion Lounges at Seattle-Tacoma airport and Philadelphia International airport on October 5, 2020, with more locations to follow.
*Amex Trendex
Methodology:
This online poll was conducted by Morning Consult poll between August 18-20, 2020 among a national sample of 2,000 general population travelers with a household income of at least $70K, and defined as adults (18+) who traveled by air at least once in 2019. Results from the survey have a margin of error of plus or minus 2 percentage points.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress , instagram.com/americanexpress , linkedin.com/company/american-express , twitter.com/americanexpress , and youtube.com/americanexpress .
Key links to products, services and corporate responsibility information: charge and credit cards , business credit cards , travel services , gift cards , prepaid cards , merchant services , Accertify , InAuth , corporate card , business travel , and corporate responsibility .
ABOUT THE CENTURION LOUNGE
The Centurion Lounge is the signature lounge program within the broader American Express Global Lounge Collection , which includes access to American Express Centurion Lounges, international American Express lounges, Delta Sky Club® for Card Members flying on Delta, Priority PassTM Select Lounges upon enrollment, Airspace Lounges, MAG U.S. Escape Lounges and Plaza Premium Lounges--a total of more than 1,300 lounges across 140 countries and counting.
Access to The Centurion Lounge is complementary and exclusive for Platinum Card Members, Centurion Members and Delta SkyMiles® Reserve Card Members. Platinum Card Members may enter with up to two travel companions at no additional charge. Centurion Members may enter with their immediate family or up to two travel companions. Platinum Card and Centurion Members may purchase access to The Centurion Lounge for additional guests for $50 each guest. Delta SkyMiles® Reserve Card Members may bring up to two guests at a per-visit rate of $50 per person, per location.
Location: Global
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005291/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom